











































































































































of  chromosome  21,  the  molecular  bases  of  its  phenotype  are  still  largely  unknown.  We  used  the  Infinium
HumanMethylation450 BeadChip to investigate DNA methylation patterns in whole blood from 29 DS persons, using their
relatives  (mothers  and  unaffected  siblings)  as  controls.  This  family‐based  model  allowed  us  to  monitor  possible
confounding effects on DNA methylation patterns deriving from genetic and environmental factors. Although differentially
methylated regions (DMRs) displayed a genome‐wide distribution, they were enriched on chromosome 21. DMRs mapped
in  genes  involved  in  developmental  functions,  including  embryonic  development  (HOXA  family)  and  haematological
(RUNX1  and  EBF4)  and  neuronal  (NCAM1)  development.  Moreover,  genes  involved  in  the  regulation  of  chromatin
structure (PRMD8, KDM2B, TET1) showed altered methylation. The data also showed that several pathways are affected in
DS,  including PI3K‐Akt signaling.  In conclusion, we  identified an epigenetic signature of DS  that sustains a  link between
developmental defects and disease phenotype, including segmental premature aging. 
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INTRODUCTION 
 
Down Syndrome (DS) results from the presence of all 
or part of an extra copy of human chromosome 21 
(HSA21) [1] and it is the most common aneuploidy in 
humans, with about 1 in 700 live births [2]. The 
disease presents a broad range of clinical signs, which 
vary among individuals and include cognitive 
disorders, physical growth defects, endocrine disorders 
with a marked susceptibility to diabetes mellitus [3], 
diseases of the respiratory system and different cancer 
types [4].  
 
DS is traditionally classified as a progeroid disease 
[5,6], as affected subjects exhibit precocious appearance 
of age-associated biomarkers like DNA damage 
accumulation and chromosomal instability [7–10]. 
However, as recently reviewed by Zigman [11], 
accelerated aging in DS is atypical and segmental, 
involving some but not all organs and tissues, in 
particular the central nervous system [12–14] and the 
immune system [15,16]. Accordingly, persons with DS 
suffer an accelerated decline of cognitive functions [14] 
and develop Alzheimer’s disease with high frequency 
[11].  Moreover DS persons present peculiar haemato-
logical abnormalities, that include abnormal platelet 
counts, macrocytosis, alterations in lymphocytes 
composition [17,18] and higher susceptibility to 
develop leukemia, including rare forms like acute 
megakaryoblastic leukemia, and other hematopoietic 
disorders [19–21]. 
 
The molecular bases of DS pathogenesis are still largely 
unknown. Transcriptomic studies using microarrays 
and, more recently, next generation sequencing 
approaches have depicted a complex picture, in which 
altered RNA expression is detected for many but not all 
HSA21 genes and for an elevated number of non-
HSA21 genes [22]. Recently, four independent studies 
started to dissect the epigenetic characteristics of DS, 
describing the DNA methylation patterns of different 
tissues at the genome wide level [23–25]. The first two 
studies used the Illumina Infinium Human-
Methylation27 BeadChip (Infinium 27k) to analyze the 
DNA methylation profiles of chorionic villi samples 
[23] and of total peripheral blood leukocytes (PBL) and 
T-lymphocytes from adults with DS [25]. More 
recently, DNA methylation of DS placenta and buccal 
epithelium was assessed by reduced representation 
bisulfite sequencing and Illumina Infiunium 
HumanMethylation450 BeadChip (Infinium 450k) 
respectively [24,26]. The studies were concordant in 
showing marked DNA methylation alterations in DS 
cells that were not enriched in HSA21, but were spread 
across the entire genome.  
Here we used the Infinium 450k to analyze whole blood 
samples from a family-based model of DS. We used an 
analysis pipeline specifically tailored for Infinium 450k 
data, decribed in Bacalini et al.. Our model was 
composed by 29 persons with DS, their mothers and 
their unaffected siblings. This family-based model 
allowed us to monitor possible confounding effects on 
DNA methylation patterns deriving from genetic and 
environmental (lifestyle) factors. In addition, compared 
to the previous study on blood cells from DS [25] that 
used the Infinium 27k array, the Infinium 450k allows a 
deeper investigation of DNA methylation profiles, with 
a particular focus on CpG islands and their surrounding 
regions (shores and shelves) that are well established 




DNA methylation profile of persons with Down 
Syndrome 
 
We used the Infinium 450k assay [28] to investigate the 
DNA methylation profile of peripheral white blood cells 
(WBC) from 29 trios composed by a DS person (DSP), 
the mother (DSM) and one non-affected sib (DSS). 
After quality check and the exclusion of chromosome X 
and Y data, we recovered 450981 out 485577 loci for 
subsequent analyses.  
 
To provide a global overview of the DNA methylation 
patterns of DS, we first compared the beta-values 
distributions of each chromosome between DSP, DSS 
and DSM. Significant differences between DSP and 
their relatives were observed for most chromosomes 
(Fig.1A). The most striking differences were observed 
in HSA21 (Fig.1A and Fig.1B), where DSP showed a 
decrease in the density of highly methylated loci with a 
concomitant enrichment in loci with methylation levels 
between 0.5 and 0.8. 
 
Cells count inference from DNA methylation data 
 
Several studies reported age-dependent defects in the 
innate and in the adaptive immune system of persons 
with DS [29], consisting in altered prevalence of the 
different lymphocyte subpopulations. Considering that 
DNA methylation is tissue and cell specific, these 
differences could bias the discovery of differentially 
methylated regions (DMRs) when comparing DNA 
methylation of WBC from DSP with non-trisomic 
subjects. We reasoned that, in order to identify intrinsic 
DNA methylation defects in WBC from DSP, 
correction for lymphocyte subpopulations prevalence 
should be implemented in statistical analysis. However, 
in our cohort blood cell type counts were available only 
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for DSP. To overcome this lack of information we 
took advantage of a recently developed algorithm to 
infer blood cell counts starting from DNA methylation 
data [30] that has been successfully applied in a study 
on rheumatoid arthritis [31]. The details of the cell 
counts estimation procedure are reported in Material 
and Methods section. The inferred cell counts 
faithfully reproduced our experimental data on DSP 















































populations (Supplementary Fig.1). In particular, DSP 
showed a significant decrease in the number of CD19+ 
B cells (p-value <0.001) and CD3+CD4+ T cells (p-
value <0.001) and a significant increase in the number 
of CD3+CD8+ T cells (p-value <0.001), leading to 
altered CD3+CD4+/CD3+CD8+ ratio, as previously 
reported [15,17]. Based on these considerations, we 
used inferred WBC counts as covariates in downstream 
















































between hypermethylated and hypomethylated  in DSP  compared  to DSS.  (C) Chromosomal enrichment of  the  identified DMRs. For
each chromosome, the Odds Ratio resulting from Fisher’s exact test is reported. Significant enrichments are indicated with asterisks. 
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Identification of differentially methylated regions 
between DSP and DSS 
 
To identify DMRs between DSP and DSS we used an 
original analysis pipeline described by Bacalini et al.. 
Briefly, this approach classifies Infinium 450k probes in 
4 Classes: i) Class A: probes in CpG islands and CpG 
islands-surrounding sequences (shores and shelves) that 
map in genic regions; ii) Class B: probes in CpG islands 
and CpG islands-surrounding regions (shores and 
shelves) which do not map in genic regions; iii) Class 
C: probes in genic regions which are not CpG rich; iv) 
Class D: probes in non-genic regions which are not 
CpG rich. Class A and Class B CpG probes were 
grouped in clusters, referred as “blocks of probes” 
(BOPs), containing the probes localized in the same 
island, in the same shore or in the same shelf. While 
Class C and Class D probes were compared between DS 
and DSS using ANOVA, Class A and Class B BOPs 
were compared using a multivariate analysis of variance 
(MANOVA), which allows to identify general changes 
in methylation of a genomic region. 
 
Sex, batch and cell types distribution were included in 
the analysis as covariates. In Class A, we identified 
4648 BOPs able to discriminate DSP from DSS (q-
value < 0.05; Fig.2A and Fig.2B). DSM methylation 
patterns were similar to those of DSS, confirming that 
the identified BOPs are specific of DS. It is worthwhile 
to note that the use of cell counts markedly reduced the 
number of identified DMRs (Supplementary Fig.2). 
Supplementary Table 1 reports the 4648 differentially 
methylated BOPs ranked on the basis of their q-value.  
Of the 6650 BOPs in Class B, 889 resulted differentially 
methylated between DSP and DSS (q-value < 0.05; 
Fig.2B and Supplementary Table 1).  
 
Methylation values of Class C and Class D probes were 
compared between DSP and DSS by ANOVA, 
correcting for sex, batch and cell types distribution. 
6051 CpG probes out of 109617 probes mapping in 
Class C and 3426 out of 54697 of probes mapping in 
Class D were differentially methylated between DSP 
and DSS (q-value < 0.05; Fig.2B and Supplementary 
Table 1). 
 
Kerkel and co-workers previously analyzed DNA 
methylation profiles in peripheral blood lymphocytes 
(PBL) from 29 DS adults and 20 age-matched controls 
using the Infinium 27k and reported a list of 
differentially methylated genes distributed across 
various autosomes, with no specific enrichment on 
HSA21. Since most of the Infinium 27k probes are also 
in the Infinium 450k array, we checked whether the 
DMRs identified in that previous study were confirmed 
in our cohort. Among the 7 probes selected as DMRs by 
Kerkel et al. (cg07991621, cg08822227, cg09554443, 
cg05590257, cg14972143, cg00983520, cg21053323) 
all but one (cg05590257) resulted differentially 
methylated also in our cohort (Supplementary Fig.3). 
However, although it did not reach statistical 
significance, a trend for differential methylation was 
evident also for cg05590257 and the surrounding CpG 
probes. 
 
When we looked at the distribution of Class A DMRs 
across the chromosomes, we found a significant 
overrepresentation of DMRs on chromosomes 21, 17, 6 
and 15 and a significant underrepresentation on 
chromosome 5 (Fisher’s exact test, p-value < 0.05; Fig. 
2C). Chromosome 21 enrichment was observed also for 
CpG probes in Class C, but not for those in Class B and 
Class D (Additional File 8, Figure S7). While in 
chromosome 17 the DMRs were scattered along the 
entire chromosome, in chromosome 6 they clustered in 
the HLA locus. As this locus is highly polymorphic, the 
observed DNA methylation differences between DSP 
and DSS could be ascribed to the presence of SNPs in 
the probes of the array. To assess this point, we 
clustered the samples on the basis of their methylation 
values in the selected HLA loci, reasoning that the 
member of the same family should share some variants 
and for that should cluster together (Supplementary 
Fig.4). However, DSP tended to cluster together, 
suggesting that, at least for some HLA loci, their 
methylation profile was different from their relatives, 
independently from the genetic background.  
    
Although HSA21 was the most affected by the 
aneuploidy, also almost all the other chromosomes were 
altered in terms of DNA methylation patterns. These 
results are consistent with those previously achieved 
with the 27k array, which however failed to identify the 
enrichment on chromosome 21, probably because of the 
lower density of probes, especially in small 
chromosomes with low number of genes.  
 
Pathway and gene ontology analyses 
 
We performed Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway and gene ontology (GO) 
analyses using the list of 4648 Class A BOPs 
differentially methylated between DS and DSS (Table 
1). The KEGG pathways that reached statistical 
significance after FDR correction were involved in 
ribosome, immune functions and type I diabetes. GO 
analysis revealed a number of enriched GO terms, with 
the selected DMRs predominantly mapping in genes 
involved in developmental processes and in the 
morphogenesis of anatomical structures.  
  




































Identification of an epigenetic signature of Down 
Syndrome 
 
To provide an unambiguous epigenetic signature of DS, 
from the list of 4648 Class A BOPs altered in DSP we 
selected a short list of DMRs whose DNA methylation 
status was remarkably different compared to healthy 
sibs. To this aim, we considered only the BOPs 
containing at least 2 adjacent CpG sites for which the 
DNA methylation difference between DSP and DSS 
was higher than 0.15, as previously suggested [32]. Of 
the 4648 BOPs selected above, 68 met these more 
stringent criteria (Supplementary Table 2). Fig. 3A 
reports the DNA methylation profile for some of the 
selected BOPs. Hierarchical clustering analysis showed 
that the methylation status of the 68 loci clearly 
separated DSP from DSS and DSM, while it did not 
distinguish DSS from DSM (Fig. 3B). 73% of the 
probes included in this epigenetic signature were 




































To investigate if our selection of CpG probes universally 
characterizes DS, independently from genetic or 
environmental factors, we took advantage of our family-
based cohort and we calculated for each DSP-DSS pair 
the difference between the methylation levels of the most 
significant CpG probe in each of the 68 BOPs. 
Hierarchical clustering of the difference values did not 
clearly distinguish any family from the others, indicating 
that the identified signature is not significantly affected 
by genetic or environmental factors (Fig. 3C).  
 
The number of loci included in the epigenetic signature 
of DS was too small to perform ontology enrichment 
analyses, however from a careful screening of the list 
four main functions emerged: 1) haematopoiesis 
(RUNX1, DLL1, EBF4 and PRMD16); 2) morphogenesis 
and development (HOXA2, HOXA4, HOXA5, HOXA6, 
HHIP, NCAM1); 3) neuronal development (NAV1, EBF4, 
PRDM8, NCAM1, GABBR1); 4) regulation of chromatin 
structure (PRMD8, KDM2B, TET1). 
Table 1. KEGG pathways and gene ontology analysis for Down Syndrome associated 
DMRs.  The  table  reports  the  significantly  enriched  KEGG  pathways  and  gene 
ontologies,  as  resulting  from  the  analysis  with  Fisher’s  exact  test  and  GOrilla 
platform (see Materials and methods section). 
 
Description q-value  
Kegg Pathway  
Ribosome 0.013 
Allograft rejection 0.013 
Graft-versus-host disease 0.013 
Cell adhesion molecules (CAMs) 0.013 
Autoimmune thyroid disease 0.013 
PI3K-Akt signaling pathway 0.013 
Basal cell carcinoma 0.013 
HTLV-I infection 0.034 
Type I diabetes mellitus 0.040 
Gene Ontology Process  
System process (GO:0003008 ) 0.027 
Anatomical structure morphogenesis (GO:0009653 ) 0.032 
Regulation of signal transduction (GO:0009966 ) 0.027 
Multicellular organismal process (GO:0032501 ) 0.000 
Single-organism process (GO:0044699 ) 0.015 
Single-multicellular organism process (GO:0044707 ) 0.000 
Positive regulation of biological process (GO:0048518 ) 0.027 
Embryonic organ morphogenesis (GO:0048562 ) 0.006 
Regulation of response to stimulus (GO:0048583 ) 0.035 
Embryonic skeletal system morphogenesis (GO:0048704 ) 0.018 
Anatomical structure development (GO:0048856 ) 0.017 
Regulation of body fluid levels (GO:0050878 ) 0.038 
  













































Finally, we validated 3 of the DMRs included in the 
epigenetic signature of DS (RUNX1 island, KDM2B N-
Shore and NCAM1 island) using an alternative method, 
the Sequenom’s EpiTYPER assay. Besides the 29 DSP 
and 29 DSS used for genome wide DNA methylation 
analysis, the validation cohort included additional 49 
DSP and 33 age- and sex- matched unrelated controls. 
EpiTYPER analysis confirmed that the CpG sites 
included in the 450k BeadChip were differentially 
methylated between DSP and controls and showed that 













































particular, in RUNX1 and KDM2B amplicons all the 
CpG sites resulted significantly hypermethylated in 
DSP respect to controls (Fig. 4A and Fig. 4B; 
Student’s t-test). On the contrary, only 7/11 of the 
CpGs assessed in NCAM1 island were significantly 
different between DSP and controls (Fig. 4C). As DS 
can be characterized by total or partial trisomy, we 
checked whether this could affect the methylation of 
these DMRs. No significant difference between free 
trisomy and translocation or mosaicism was found 
(data not shown). 


















































In this study we investigated the epigenetic status, in 
terms of DNA methylation, of WBC from DS persons 
(DSP), in comparison with their mothers (DSM) and 
unaffected sibs (DSS). This family-based model was 
chosen in order to minimize confounding genetic and 
environmental factors.  
 
Our analysis showed that DS is characterized by a 
profound rearrangement of genome-wide DNA 
methylation patterns. Overall distributions of DNA 
methylation values resulted significantly different 
between DSP and their unaffected sibs (and mothers) 
for most chromosomes, but these differences were 
particularly marked for HSA21. Accordingly, region-
centric and site-specific analyses identified a large 
number of DMRs that, although mapping to all 
chromosomes, were enriched in HSA21 for Class A and 
Class C probes. This result is particularly interesting, as 
the probes in these two classes are associated to genic 
sequences (Bacalini et al.). As the Infinium 450k 
provides an estimate of the mean methylation status of 
the DNA hybridized to the array, it is difficult to say if 
only the extra copy of HSA21 is aberrantly methylated 
or if DNA methylation changes affect all the 3 copies of 
HSA21. Future studies should address this point by 
analyzing allele-specific DNA methylation. DMRs 
enrichment in HSA21 was not observed in the three 
studies that have previously analyzed DNA methylation 
patterns in DS, but this discrepancy could be ascribed to 
the different experimental procedures, analytical 
protocols, analyzed tissues and/or age classes of the 
probands. However, it is worth to note that our analysis 
confirmed the majority of DMRs previously identified 
in PBL from DS [25]. 
 
We observed a prevalent hypermethylation of DS 
DMRs, although less pronounced than the one described 
in placental tissue [24]. Interestingly, Jin and coworkers 
have proposed that these hypermethylation events occur 
early during development as a consequence of 
downregulation of TET enzymes and/or of REST 
transcription factor. In our dataset, REST N-shore 
resulted slightly hypermethylated in DSP, potentially 
confirming downregulation of REST mRNA in DS, 
while TET1 S-shore was hypomethylated. To 
investigate the reasons of this discrepancy, it would be 
interesting to experimentally verify if TET1 altered 
expression in DSP is tissue-dependent and how DNA 
methylation could regulate its transcription.  
 
Starting from the list of Class A DMRs, we defined an 
epigenetic signature of DS in WBC by selecting a short 
list of DMRs that show a methylation difference 
between DSP and DSS greater than 0.15 and that can be 
functionally linked to the various phenotypic aspects of 
the disease. Among the genes included in the signature 
there is RUNX1, which encodes for a transcription 
factor that is pivotal in the development of 
haematopoietic cells and that can be involved in acute 
myeloid leukaemia [33,34], whose frequency is high 
among DSP. Another gene that could account for the 
haematological defects in DSP is EBF4, which belongs 
to a family of transcription factors involved in B-cell 
maturation [35]. Consistently, B lymphocytopenia is a 
main immunological characteristic of DS [15,17,36]. 
The signature includes also genes belonging to the 
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HOXA cluster, whose fine tuning during development, 
also through epigenetic mechanisms, is a crucial 
determinant of embryonic cell fate [37]. Interestingly, 
we found that the selected DMRs mapped also to genes 
that are involved in the development of tissues other 
than the blood, in primis the central nervous system 
(CNS). Although the methylation profiles are highly 
tissue-specific, these alterations of DNA methylation in 
WBC can be clues of epigenetic defects in other tissues, 
such as the CNS, that can contribute to DS 
pathogenesis. Finally, our short list included genes 
involved in the regulation of chromatin [38], such as 
TET1 and KDM2B, an histone lysine demethylase that 
in mouse embryonic stem cells recruits the polycomb 
repressive complex 1 (PRC1) to CpG islands of early 
lineage-specific genes [39,40]. As KDM2B has also 
been shown to repress the expression of ribosomal 
genes, its hypermethylation could account for the 
increase in ribosomal gene activity previously observed 
in lymphocytes from persons with DS [41,42]. 
Importantly, we showed that the selected DNA 
methylation changes were common to all the analyzed 
DSP, independently from their genetic and 
environmental background, and were reproducible in an 
independent cohort.  
 
Our analysis supports the perspective of DS as a 
developmental disease [43], as many of the identified 
DMRs are involved in morphogenetic and 
developmental processes. This observation poses the 
basis for a link between intrinsic defects that are 
established early during development [29,44,45] and DS 
phenotype, including the precocious functional aging of 
specific tissues. Indeed, as described above, we 
identified genes with altered DNA methylation that are 
involved in the development of nervous and immune 
systems, which both show an aged phenotype in DS.  
 
Also KEGG results provided interesting insights into 
the molecular basis of DS phenotype. PI3K-Akt 
signaling pathway regulates fundamental cellular 
functions, such as protein synthesis and cell 
proliferation, and has key roles in aging [46,47]. Three 
independent groups have recently demonstrated that the 
PI3K/Akt/mTOR pathway is deregulated in DS and that 
this event occurs early in development [48–50]. 
Combining these observations with our results we can 
speculate that early alteration in methylation of genes 
involved in PI3K/Akt/mTOR can contribute to DS 
phenotype, including signs of premature aging. KEGG 
analyses sustain also a strong link between aneuploidy-
linked DNA methylation changes and the higher 
prevalence of immunological disorders in persons with 
DS [29,51]. In this sense it is worth to note that in DS 
the methylation profile of the HLA locus on 
chromosome 6 is heavily altered. Although we cannot 
exclude that a significant fraction of these differences 
between DSP and DSS can be ascribed to the highly 
polymorphic nature of the region and to inter-individual 
variations of its methylation profiles [52], that could 
have hampered our analysis, we are tempted to 
speculate that changes in DNA methylation could affect 
HLA regulation, thus contributing to immunological 
and autoimmune defects in DS. 
 
Two main theories have been formulated in the last 
decades to unravel the molecular bases of DS 
pathogenesis [53]. According to the reductionistic 
theory, a “Down Syndrome critical region” (DSCR) on 
HSA21 [54] includes a limited number of dosage-
sensitive genes whose trisomy results in the profound 
phenotypic alterations of DS. In this perspective, DS 
pathogenesis should map to a specific genetic regions of 
HSA21. As an alternative to the DSCR theory, the 
“organicist concept” centers the DS pathogenesis on the 
developmental process and suggests that the presence of 
a trisomic chromosome, beside the specific function of 
the genes that it contains, disrupts on the whole the 
genetic homeostasis and leads to developmental 
instability. Both murine [55,56] and human models 
[57,58] have recently argued against the existence of a 
unique DSCR, proposing that HSA21 contains different 
susceptibility regions that can contribute to the DS 
phenotype. Based on these and on other data, current 
researchers favour a synthesis of the two theories, in 
which the combination of the trisomy of multiple 
HSA21 genes, none of which is by itself critical for the 
disease, induces a wide-range cascade of events that 
through physical and functional interactions engages 
many non-HSA21 genes and results in a global 
remodeling of genomic function.  Our results support 
this view, as we identified DS associated DMRs that, 
although enriched on HSA21, interest most of the other 
chromosomes and are functionally linked to the 
developmental defects characteristic of the disease. 
Future studies should investigate the origin of the 
observed DNA methylation defects in DS. A link 
between alterations in DNA methylation patterns and 
genetic defects in genes with epigenetic functions has 
been established for many diseases, including 
immunodeficiency, centromeric regions Instability and 
Facial anomalies Syndrome (ICF), Rett Syndrome and 
cancer [59]. In the case of DS, this connection appears 
less clear. It is interesting to note that among the genes 
on HSA21 there is DNMT3L, which encodes for a 
protein that, although missing enzymatic activity, assists 
de novo DNA methyltransferases in establishing DNA 
methylation marks [60]. The trisomic status of 
DNMT3L could therefore affect the establishment of 
DNA methylation patterns during development. 
  
www.impactaging.com                     89                                     AGING, February 2015, Vol. 7 No.2
Moreover, while some methylation changes could be 
directly caused by alterations in signal transduction 
cascades due to gene-dosage imbalances, other DNA 
methylation variations could be caused by feedback 
mechanisms that try to buffer RNA expression defects 
in trisomic cells. Finally, changes in DNA methylation 
profiles could be ascribed also to the perturbation of the 
conserved but fine-tuned network of chromosome 




Samples. Persons with DS (DSP) who participated to 
this study were part of a larger open-label study on 
cognitive decline in DS described elsewhere (Ghezzo et 
al., 2014). The study was approved by the local Ethical 
Committee (S. Orsola Hospital, University of Bologna; 
ethical clearance #126/2007/U/Tess, released on 
December 18, 2007). Written informed consent to 
participate in the study was obtained from adult DS 
persons and from parents or authorised tutors for those 
under age. Written informed consent was also obtained 
for adult DS persons from parents or relatives 
(brothers/sisters). Subjects were recruited with the help 
of CEPS, OPIMM and ANFFAS, three local non-profit 
associations dealing with DS persons operating in the 
eastern part of Emilia-Romagna Region (Bologna and 
Ferrara provinces). Participation in the study was on a 
totally voluntary basis, with no reward for the 
participants or their families. Exclusion criteria were 
current acute illnesses, hepatic, renal or cardiac 
insufficiency, assumption of antioxidant or nutraceutical 
substances (vitamins, lipoic acid, acetylcysteine, omega 
3 and 6 fatty acids, probiotics) within the last two 
months, as detailed elsewhere [14] A total of 29 DSP 
(12-43 years, 18 males, 11 females), 29 DSS (9-52 
years, 7 males, 22 females) and 29 DSM (42-83 years) 
were included in the study. All the DSP were classified 
as free trisomy with the exception of 3 translocations 
and 4 mosaicisms. 
 
DNA extraction and bisulphite treatment of DNA. 
Extraction of genomic DNA from whole peripheral 
blood was performed using the QIAamp 96 DNA Blood 
Kit (QIAGEN, Hilden, Germany). Sodium bisulphite 
conversion for Infinium HumanMethylation450 
BeadChip and for Sequenom EpiTYPER assay was 
performed using the EZDNA Methylation-Gold Kit and 
the EZ-96 DNA Methylation Kit respectively, as 
previously described [61]. 
 
Genome-wide DNA methylation analysis. Genome-
wide DNA methylation of 29 families including a DSP, 
a DSM and a DSS was analyzed using the Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, 
CA) following manufacturer’s instructions. Arrays were 
scanned by HiScan (Illumina). GenomeStudio 
(Illumina) was used to perform background subtraction, 
while IMA R package [62] was used to pre-process the 
β-values. All the samples were retained, as none had 
more than 75% of the probes with a detection p-value 
greater than 1e-05. 425 probes had a detection p-value 
greater than 0.05 in more than 75% samples and were 
removed, together with the probes containing missing 
values (23437) and those localized on sexual 
chromosomes. Based on these quality checks, 450981 
out of 485577 CpG were retained.  
 
Statistical analysis. For each chromosome, beta-values 
distributions in DSP, DSS and DSM were reported as 
100-bins histograms, that were compared using 
Kolmogorov-Smirnov test.  Bonferroni correction was 
performed to correct for multiple testing. 
 
The RELATION_TO_UCSC_CPG_ISLAND and the 
UCSC_REFGEN_NAME columns in the Illumina 
output were used to subset the array probes in four 
classes and to group probes in BOPs, as described in 
Bacalini et al.. Class A included 229232 probes grouped 
in 73442 BOPs, 30400 of which included 2 or more 
probes (176211 probes); Class B included 57370 probes 
grouped in 32176 BOPs, 6650 of which included 2 or 
more probes (28051 probes); Class C 109617 probes; 
Class D included 54762 probes. 
 
For Class A and Class B, BOPs methylation values 
were compared between DS and DSS using the 
MANOVA function from the R package car. BOPs 
containing one or 2 CpG probes were excluded from the 
analysis and MANOVA was applied on sliding 
windows of 3 consecutive CpGs within the same BOP. 
For each BOP, we kept the lowest p-value among those 
calculated for the different sliding windows. For Class 
C and Class D, the methylation values of the probes 
were compared between DS and in DSS using the 
ANOVA function from the R package car. Both for 
MANOVA and ANOVA analysis, correction for sex, 
batch and cell counts (see the next paragraph) were 
performed. To correct for multiple testing, we applied a 
Benjamini-Hochberg False Discovery Rate correction 
using the function mt.rawp2adjp from the R package 
multtest. Gene ontology annotation of selected DMRs 
was performed using gene ontology enrichment analysis 
and visualization tool http://cbl-gorilla.cs.technion.ac.il/ 
[63]. For KEGG pathways, the significance analysis 
was performed using a two tailed Fisher’s exact test for 
each pathway [64]. 
 
Estimation of cell counts. We used a previously 
published algorithm [30] to infer white blood cell 
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counts from DNA methylation data. Starting from cell-
specific DNA methylation signatures of purified 
leukocyte samples (validation dataset), the method 
selects n CpG sites with the highest informativeness 
with respect to blood cell types and uses this 
information to predict leukocytes distribution in the 
target dataset. To our knowledge, two validation 
datasets are currently available in public databases. In 
the first dataset (GEO Accession number GSE39981), 
DNA methylation profiles of 46 samples (6 CD19+ B 
cells samples, 8 granulocytes samples, 5 CD14+ 
monocytes samples, 11 CD56+ NK cells samples, 8 
CD3+CD4+T cells samples, 2 CD3+CD8+ T cells 
samples, 1 CD3+CD56+ NK sample and 5 CD3+ T 
cells samples) were analyzed by the Infinium 27k. The 
second dataset (GEO Accession number GSE35069) 
includes data from the Infinium 450k on seven sorted 
cell populations (CD4+ T cells, CD8+ T cells, CD56+ 
NK cells, CD19+ B cells, CD14+ monocytes, 
neutrophils, and eosinophils) from six healthy males. 
We tested the performance of both validation sets by 
comparing the predicted leukocytes distributions with 
flow cytometry results available for DS. Although both 
datasets were successful in predicting experimentally 
measured cell counts, we noticed that the GSE35069 
was less effective in predicting specific cell types such 
as CD56+ NK cells (Supplementary Figure 2A-D). This 
difference persisted also when we tried to use different 
sets of informative CpG sites selected from the two 
validation datasets (100, 300, 500, 1000, 2000 CpG 
sites from the GSE39981 dataset; 100, 300, 500, 1000, 
5000, 10000 and 20000 CpG sites from the GSE35069 
dataset). Based on these considerations, we decided to 
use GSE39981 as validation dataset and we estimated 
the distribution of CD19+ B cells, CD3+CD4+ T cells, 
CD3+CD8+ T cells, granulocytes, CD14+ monocytes 
and CD56+ NK cells using the 500 most informative 
CpG sites, 453 of which were included in the Infinium 
450k. Projections of cell types distributions for DS, DSS 
and DSM are reported in Supplementary Figure 2B.   
 
Locus-specific DNA methylation analysis. The 
EpiTYPER assay (Sequenom, San Diego, CA) was used 
for the quantitative analysis of DNA methylation of 
CpGs in RUNX1 CpG island (chr21:36,258,992-
36,259,453), KDM2B N-Shore (chr12:121,973,796-
121,974,353) and NCAM1 island (chr11:112,834,144-
112,834,547). 10 ng of bisulphite-treated DNA were 
PCR-amplified and processed following manufacturer’s 
instructions. Bisulphite specific primers were the 
following: RUNX1_Forward: aggaagagagGGTAGGAG 
TTGTTTGTAGGGTTTTAAT; RUNX1_Reverse: cagta 
atacgactcactatagggagaaggctCCCACATCCCAAACTA
AAAAAA; KDM2B_Forward: aggaagagagGGGATTT 
TGATTATTTTATTGTTAGTTT; KDM2B_ Reverse: 
cagtaatacgactcactatagggagaaggctAAAACCCCTCCCT







DNA methylation data have been submitted to the 
NCBI Gene Expression Omnibus (GEO) 
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blood DNA methylation profile of  the BOPs containing  the CpG probes  reported  in  (A). The probe cg09554443
maps to a non CpG rich region of the CD247 gene and the corresponding BOP is not reported. 
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Supplementary Figure 4. Hierarchical clustering of DSP, DSS and DSM
for significative BOPs mapping  in HLA  loci. For the 21 BOPs mapping  in
HLA loci, the CpG probes differentially methylated between DSP and DSS
were  selected  (ANOVA,  q‐value  <0.05;  46  CpG  probes).  The  heatmap
reports  DNA  methylation  values  for  the  selected  CpG  probes  (CpG
probes  in  rows,  samples  in  columns  and  color‐coded).  Dendrograms
depicts hierarchical clustering of probes and samples. 
